BG106406A - Пиримидин-2,4,6-трионови металопротеиназни инхибитори - Google Patents

Пиримидин-2,4,6-трионови металопротеиназни инхибитори

Info

Publication number
BG106406A
BG106406A BG06406A BG10640602A BG106406A BG 106406 A BG106406 A BG 106406A BG 06406 A BG06406 A BG 06406A BG 10640602 A BG10640602 A BG 10640602A BG 106406 A BG106406 A BG 106406A
Authority
BG
Bulgaria
Prior art keywords
pyrimidine
metalloproteinase inhibitors
trione metalloproteinase
trione
disorders
Prior art date
Application number
BG06406A
Other languages
English (en)
Inventor
Julian Blagg
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106406A publication Critical patent/BG106406A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретението се отнася до пиримидин-2,4,6-трионови металопротеиназни инхибитори с формула, в коятоХ, Y, Ar1, Z, R1, R2 и R3 имат значения, посоченив описанието, до фармацевтични състави и до методи за лечение на възпаления, рак и други заболявания.
BG06406A 1999-08-12 2002-02-12 Пиримидин-2,4,6-трионови металопротеиназни инхибитори BG106406A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14854799P 1999-08-12 1999-08-12
PCT/IB2000/001090 WO2001012611A1 (en) 1999-08-12 2000-08-03 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BG106406A true BG106406A (bg) 2002-09-30

Family

ID=22526231

Family Applications (1)

Application Number Title Priority Date Filing Date
BG06406A BG106406A (bg) 1999-08-12 2002-02-12 Пиримидин-2,4,6-трионови металопротеиназни инхибитори

Country Status (41)

Country Link
US (1) US6579982B1 (bg)
EP (1) EP1202974B1 (bg)
JP (1) JP2003507371A (bg)
KR (2) KR20020047119A (bg)
CN (1) CN1156454C (bg)
AR (1) AR025091A1 (bg)
AT (1) ATE309224T1 (bg)
AU (1) AU773751B2 (bg)
BG (1) BG106406A (bg)
BR (1) BR0013081A (bg)
CA (1) CA2381551A1 (bg)
CO (1) CO5180629A1 (bg)
CR (1) CR6565A (bg)
CZ (1) CZ2002355A3 (bg)
DE (1) DE60023903D1 (bg)
EA (1) EA004680B1 (bg)
EC (1) ECSP003610A (bg)
EE (1) EE200200069A (bg)
GE (1) GEP20053424B (bg)
GT (1) GT200000137A (bg)
HK (1) HK1045995B (bg)
HN (1) HN2000000137A (bg)
HR (1) HRP20020129A2 (bg)
HU (1) HUP0202501A3 (bg)
IL (1) IL148035A0 (bg)
IS (1) IS6248A (bg)
MA (1) MA26812A1 (bg)
MX (1) MXPA02001561A (bg)
NO (1) NO20020662L (bg)
NZ (1) NZ516562A (bg)
OA (1) OA12000A (bg)
PA (1) PA8498701A1 (bg)
PE (1) PE20010491A1 (bg)
PL (1) PL353871A1 (bg)
SK (1) SK1652002A3 (bg)
TN (1) TNSN00169A1 (bg)
TR (1) TR200200381T2 (bg)
UY (1) UY26285A1 (bg)
WO (1) WO2001012611A1 (bg)
YU (1) YU6602A (bg)
ZA (1) ZA200201070B (bg)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2425283A1 (en) * 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SK4872003A3 (en) * 2000-10-26 2004-08-03 Pfizer Prod Inc Metaloproteinase pyrimidine-2,4,6-trione inhibitors
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
ES2231708T3 (es) 2001-02-14 2005-05-16 Warner-Lambert Company Llc Benzotiadicinas inhibidoras de metaloproteinasa de matriz.
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
AU2002346729A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2003090751A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
MXPA04008563A (es) * 2002-04-26 2004-12-06 Pfizer Prod Inc Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
EP1501833B1 (en) * 2002-04-26 2005-11-02 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
EP1553949B1 (en) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004014892A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US20150366275A1 (en) * 2014-06-19 2015-12-24 Gyula Cserfoi Wearable Signaling Device
GB201705255D0 (en) 2017-03-31 2017-05-17 Univ I Tromsø - Norges Arktiske Univ Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000035917A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,4-헤테로고리성 메탈로프로테아제 저해제
KR20010014020A (ko) * 1997-06-21 2001-02-26 로셰 디아그노스틱스 게엠베하 항전이성 및 항종양성 활성을 갖는 바르비투르산 유도체

Also Published As

Publication number Publication date
SK1652002A3 (en) 2002-09-10
EP1202974B1 (en) 2005-11-09
WO2001012611A1 (en) 2001-02-22
EP1202974A1 (en) 2002-05-08
ATE309224T1 (de) 2005-11-15
GEP20053424B (en) 2005-01-25
YU6602A (sh) 2004-11-25
HK1045995A1 (en) 2002-12-20
IL148035A0 (en) 2002-09-12
HN2000000137A (es) 2001-02-02
US6579982B1 (en) 2003-06-17
CZ2002355A3 (cs) 2002-07-17
MXPA02001561A (es) 2002-07-02
TR200200381T2 (tr) 2002-05-21
PA8498701A1 (es) 2002-08-26
PE20010491A1 (es) 2001-04-25
AU773751B2 (en) 2004-06-03
EA200200058A1 (ru) 2002-06-27
EE200200069A (et) 2003-04-15
HUP0202501A3 (en) 2003-02-28
CR6565A (es) 2004-02-23
KR20040073608A (ko) 2004-08-19
NZ516562A (en) 2003-06-30
UY26285A1 (es) 2001-03-16
HUP0202501A2 (hu) 2002-12-28
JP2003507371A (ja) 2003-02-25
CO5180629A1 (es) 2002-07-30
BR0013081A (pt) 2002-04-23
ECSP003610A (es) 2002-03-25
IS6248A (is) 2002-01-25
AR025091A1 (es) 2002-11-06
EA004680B1 (ru) 2004-06-24
OA12000A (en) 2006-04-18
NO20020662L (no) 2002-04-09
GT200000137A (es) 2002-02-01
ZA200201070B (en) 2003-04-30
TNSN00169A1 (fr) 2005-11-10
CN1156454C (zh) 2004-07-07
MA26812A1 (fr) 2004-12-20
HK1045995B (zh) 2004-12-31
CN1368963A (zh) 2002-09-11
HRP20020129A2 (en) 2004-04-30
NO20020662D0 (no) 2002-02-11
DE60023903D1 (de) 2005-12-15
PL353871A1 (en) 2003-12-01
KR20020047119A (ko) 2002-06-21
AU6010500A (en) 2001-03-13
CA2381551A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
BG106406A (bg) Пиримидин-2,4,6-трионови металопротеиназни инхибитори
WO2002034726A3 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
AP2001002318A0 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2003091259A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
MY121294A (en) Novel hexanoic acid derivatives.
BG105653A (bg) Ароматни хетероциклени съединения като противовъзпалителни средства
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
BG105880A (bg) Съединения полезни като противовъзпалителни средства
BG106013A (bg) Нови съединения и състави като протеазни инхибитори
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
AR023777A1 (es) Nuevos compuestos
BG105731A (bg) 3,3-биарилпиперидинови и 2,2-биарилморфолинови производни
AU1182702A (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
UY27772A1 (es) Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
HK1077303A1 (en) Hexacyclic compounds
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
MY127819A (en) Optically pure camptothecin analogues
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.